+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid improves liver and renal biological parametes in liver transplant patients treated with neoral



Ursodeoxycholic acid improves liver and renal biological parametes in liver transplant patients treated with neoral



Gastroenterology 114(4 Part 2): A1219




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144832

Download citation: RISBibTeXText


Related references

Sandimmun Neoral: Taiwanese experience in renal transplant patients with special reference to patients with existing liver disease. Transplantation Proceedings 28(3): 1327, 1996

Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. Transplantation Proceedings 28(4): 2232-2233, 1996

Does prophylactic ursodeoxycholic acid treatment of liver transplant patients prevent acute rejection?. Hepatology 27(6): 1748-1749, 1998

Cyclosporine peak levels provide a better correlation with the area-under-the-curve than trough levels in liver transplant patients treated with neoral. Transplantation Proceedings 30(4): 1462-1463, 1998

Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis. Journal of Hepatology 2019, 2019

Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement. European Journal of Gastroenterology & Hepatology 28(6): 645-649, 2016

Renal function in liver transplant recipients receiving Neoral versus tacrolimus. Journal of the American Society of Nephrology 7(9): 1926, 1996

The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients. Transplantation 63(11): 1591-1594, 1997

Ursodeoxycholic acid udca treatment improves liver disease and nutritional state in cystic fibrosis cf patients with chronic cholestasis. Gastroenterology 96(5 Part 2): A586, 1989

Efficacy of C0 and C2 monitoring in adult liver transplant recipients treated with neoral, mycophenolate mofetil, and steroids. Transplantation Proceedings 39(10): 3234-3236, 2007

Increase of sulfated ursodeoxycholic acid in the serum and urine of patients with chronic liver disease after ursodeoxycholic acid therapy. Journal Of Gastroenterology & Hepatology. 11(4): 385-390, 1996

Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid. Digestive and Liver Disease 32(4): 318-328, 2001

Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid. Digestive & Liver Disease 32(4): 318-328, 2000

The effect of ursodeoxycholic acid udca on liver function and bile acid metabolism in patients with cystic fibrosis cf and liver disease. Hepatology 10(4): 726, 1989

Transfer of liver transplant patients from Sandimmun to Neoral. Johnson, R Round Table Series Royal Society of Medicine Press; Rational use of Neoral 30-34, 1996